Top Markets
Coin of the day
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.

CANF
Pozycja w akcjach #40863
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical... Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Cena akcji
$1.63
Kapitalizacja rynkowa
$70.02K
Zmiana (1 dzień)
-2.11%
Zmiana (1 rok)
-81.59%
Kraj
IL
Handel Can-Fite BioPharma Ltd. (CANF)

Kategoria

Historia ceny akcji dla Can-Fite BioPharma Ltd. (CANF)
Najwyższa cena zamknięcia: $1.66 dnia 2026-08-01

Najniższa cena zamknięcia: $24.37K dnia 2005-10-01
Historia cen akcji firmy Can-Fite BioPharma Ltd. od 2005 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -49.64%
2025 -43.75%
2024 -24.49%
2023 -71.44%
2022 -41.01%
2021 -30.93%
2020 -44.45%
2019 -81.47%
2018 -15.17%
2017 -35.77%
2016 -28.43%
2015 -18.01%
2014 -43.11%
2013 45.74%
2012 -26.76%
2011 -36.90%
2010 11.80%
2009 153.06%
2008 -65.95%
2007 -25.91%
2006 -8.50%
2005 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$524.97 32.59%
US
$863.52 33.55%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE